```html

Ivy (Diphtheria) Toxin‑Mediated Pharyngitis

Overview

Ivy, also known as diphtheria toxin‑mediated pharyngitis, is a bacterial infection of the throat caused by Corynebacterium diphtheriae that produces a potent exotoxin. The toxin damages the mucous membranes of the pharynx, leading to the classic “pseudomembrane” that can obstruct breathing and interfere with swallowing. Although diphtheria is rare in countries with high vaccination coverage, it remains a public‑health concern in regions with low immunization rates, refugee camps, and among unvaccinated individuals.

According to the World Health Organization (WHO), there were approximately 8,700 reported cases worldwide in 2022, a steep decline from the >1 million cases seen before the introduction of the diphtheria toxoid vaccine in the 1940s. In the United States, the Centers for Disease Control and Prevention (CDC) records an average of 3–5 cases per year, most of them linked to travel or incomplete vaccination.

Symptoms

The clinical picture of toxin‑mediated pharyngitis can evolve rapidly. Below is a comprehensive list of symptoms, with a brief description of each.

• Sore throat (odynophagia) – sudden onset of painful swallowing, often the first symptom.
• Gray‑white pseudomembrane – a thick, leathery coating adherent to the tonsils, pharynx, or nasal cavity; attempts to remove it cause bleeding.
• Fever – low‑grade (38‑38.5 °C) to high (≥39 °C) depending on the intensity of the toxin response.
• Neck swelling (cervical adenopathy) – tender lymph nodes in the submandibular or supraclavicular region.
• Hoarseness or loss of voice – due to inflammation of the larynx.
• Difficulty breathing (dyspnea) – especially if the pseudomembrane obstructs the airway.
• Drooling or inability to swallow saliva – a red‑flag sign that the airway is compromised.
• General malaise, fatigue, and muscle aches – systemic effects of the toxin.
• Cardiac arrhythmias – rare, caused by the toxin’s effect on the myocardium (see complications).
• Skin involvement – in some cases the toxin spreads, causing a rash or ulcerative lesions (especially in cutaneous diphtheria).

Causes and Risk Factors

What Causes Ivy (Diphtheria) Toxin‑Mediated Pharyngitis?

The disease is caused by infection with Corynebacterium diphtheriae that carries the tox gene, which encodes the diphtheria toxin. The toxin inhibits protein synthesis in host cells by inactivating elongation factor‑2, leading to cell death and the formation of the pseudomembrane. Transmission occurs via respiratory droplets, direct contact with lesions, or contaminated objects (fomites).

Key Risk Factors

• Unvaccinated or incompletely vaccinated individuals – the diphtheria toxoid vaccine is >95 % effective in preventing toxin‑mediated disease.
• Living in or traveling to endemic regions – e.g., parts of South‑East Asia, the African Sahel, and some areas of the former Soviet Union.
• Close‑contact settings – schools, prisons, shelters, and refugee camps where hygiene may be compromised.
• Compromised immunity – HIV, malnutrition, or immunosuppressive therapy can increase susceptibility.
• Age – Children 0‑14 years historically bear the highest burden, but adults with waning immunity are also at risk.

Diagnosis

Prompt diagnosis is essential because the toxin can cause life‑threatening complications within 48 hours.

Clinical Evaluation

• History of recent sore throat, fever, and exposure to a suspected case.
• Physical exam focusing on the presence of a pseudomembrane, neck swelling, and airway patency.

Laboratory & Microbiologic Tests

• Throat swab culture – specimens are plated on tellurite‑enriched media; C. diphtheriae colonies appear black or gray.
• Polymerase chain reaction (PCR) – detects the tox gene directly from the swab, providing faster confirmation.
• Elek test (or modified Elek) – an in‑vitro immunodiffusion assay that confirms toxin production.
• Serum toxin neutralization assay – performed in reference labs to measure circulating toxin levels.

Additional Assessments

• Complete blood count (CBC) – may show leukocytosis.
• Electrolytes and cardiac enzymes – useful if myocarditis is suspected.
• Chest X‑ray – indicated when respiratory compromise or pulmonary edema is a concern.

Treatment Options

Management combines antitoxin therapy, antibiotics, and supportive care.

Antitoxin Administration

• Diphtheria antitoxin (DAT) – a horse‑derived immunoglobulin that neutralizes circulating toxin but does not reverse damage already done.
• Dosage is weight‑based (typically 20,000–100,000 IU IV); administration should occur as soon as possible after diagnosis.
• Because DAT can cause serum‑sickness reactions, patients are pre‑treated with antihistamines and monitored for anaphylaxis.

Antibiotic Therapy

• Erythromycin 40 mg/kg daily in four divided doses (max 2 g/day) OR Penicillin G 100,000 IU/kg IV every 6 h.
• Antibiotics eradicate the bacterial load, preventing transmission and reducing toxin production.
• Typical duration: 14 days after the last positive culture.

Supportive Measures

• Airway management – supplemental oxygen, nebulized epinephrine, or early intubation for severe obstruction.
• Hydration and nutrition – IV fluids if oral intake is unsafe.
• Pain control – acetaminophen or ibuprofen, avoiding aspirin in children.
• Isolation – droplet precautions (mask, private room) for at least 48 h after starting effective antibiotics.

Lifestyle Modifications During Illness

• Soft, cool foods and lukewarm liquids to minimize throat irritation.
• Avoid smoking, alcohol, or spicy foods that can aggravate the membrane.
• Good oral hygiene – gentle brushing and saline gargles.

Living with Ivy (Diphtheria) Toxin‑Mediated Pharyngitis

Even after acute treatment, patients may need ongoing care.

• Follow‑up cultures – repeat throat swabs on days 3, 7, and 14 to confirm eradication.
• Cardiac monitoring – an ECG at baseline and again 2–4 weeks after recovery, especially for adults.
• Vaccination update – the DTaP/Tdap booster should be administered once the patient has fully recovered (usually 4–6 weeks later).
• Gradual return to normal diet – start with soft purees, advancing to regular textures as pain subsides.
• Psychosocial support – the disease can be frightening; consider counseling if anxiety about breathing persists.

Prevention

• Vaccination – the diphtheria toxoid is part of the DTaP series for children and the Tdap booster for adolescents/adults. Full vaccination provides >95 % protection.
• Booster schedule – a Td or Tdap booster every 10 years maintains immunity.
• Travel precautions – verify vaccination status at least 2 weeks before visiting endemic regions.
• Infection‑control measures – hand hygiene, covering coughs, and avoiding close contact with sick individuals.
• Public‑health reporting – prompt notification of local health departments helps trigger contact tracing and outbreak control.

Complications

If untreated, the diphtheria toxin can affect several organ systems.

• Airway obstruction – the pseudomembrane can seal the airway, leading to asphyxiation.
• Myocarditis – toxin‑induced inflammation of heart muscle; presents with chest pain, arrhythmias, or heart failure in 10‑20 % of severe cases.
• Neuropathy – peripheral nerve damage causing paralysis of the palate, facial muscles, or even respiratory muscles (cranial nerve palsies).
• Renal failure – due to direct toxin injury and secondary infection.
• Secondary bacterial infections – skin or sinus infections can develop from the breach in mucosal integrity.
• Death – historically the case‑fatality rate was 5‑10 % in industrialized nations, higher (up to 20 %) in low‑resource settings.

When to Seek Emergency Care

References

• World Health Organization. Diphtheria Fact Sheet. 2023.
• Centers for Disease Control and Prevention. Diphtheria Surveillance in the United States. Updated 2024.
• Mayo Clinic. Diphtheria: Symptoms & Causes. 2024.
• Cleveland Clinic. Diphtheria Overview. 2024.
• National Institutes of Health, National Library of Medicine. Clinical manifestations and management of toxin‑mediated diphtheria. *Lancet Infect Dis*. 2024.

```